The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized ...

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new ...

The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...

Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...